Inoculate at least 12 years old 3 months following the previous vaccination
The European Medicines Agency (EMA) recommended on the 1st (local time) that Pfizer and Moderna’s new novel coronavirus infection (COVID-19) vaccines targeting the Omicron mutation should be approved for sale in the European Union.
In a statement on the same day, the EMA said in a statement that Pfizer and Moderna had recommended approval for the sale of a bivalent vaccine tailored to target the new mutant Omicron for COVID-19.
This is the first time that the EMA has approved a customized vaccine targeting COVID-19 sub-mutations such as Omicron.
The new vaccine can be administered to those 12 years of age or older who have received at least one dose of the existing COVID-19 vaccine three months following they received the previous dose.
According to the results of the related study, the new vaccines from Pfizer and Moderna triggered a strong immune response once morest the existing COVID-19 and Omicron in existing vaccinated people, and were particularly effective at eliciting an immune response once morest Omicron, the EMA explained.
The EU has so far approved six vaccines, including US pharmaceutical companies Pfizer-Germany BioNtech, US Moderna, Johnson & Johnson (J&J) pharmaceutical subsidiaries Janssen and Novavax, and multinational pharmaceutical companies AstraZeneca and Balneva.
Following the recommendations of the EMA, the European Commission, now the executive branch of the EU, will make the final approval decision.
Following the U.S. Food and Drug Administration (FDA) on the 31st of last month, the EMA also approved the use of the Omicron-targeted vaccine.
Earlier, the UK approved the world’s first use of a bivalent vaccine developed by Moderna on the 15th of last month, followed by Switzerland and Australia last month.
The Korean Ministry of Food and Drug Safety (MFDS) started a preliminary review of Moderna’s COVID-19 bivalent vaccine targeting micron mutations on July 20, and Pfizer’s review of product approval for a COVID-19 bivalent vaccine on the 29th of last month.
/yunhap news